Web Results


Forest Laboratories was a company in the pharmaceutical industry incorporated in Delaware, with its principal office in New York City. It was known for licensing European pharmaceuticals for sale in the United States. On July 1, 2014, the company was acquired by Actavis (now Allergan).


Forest Laboratories Acquisition. Forest Laboratories Acquisition. Actavis plc and Forest Laboratories, Inc. announced on February 18, 2014 that they have entered into a definitive agreement under which Actavis will acquire Forest for a combination of cash and equity valued at approximately $25 billion. The transaction will ...


4 days ago ... Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma .


Learn about working at Forest Laboratories (now Allergan). Join LinkedIn today for free. See who you know at Forest Laboratories (now Allergan), leverage your professional network, and get hired.


Forest Laboratories, LLC develops, manufactures, and sells branded forms of ethical drug products in the United States and Europe. Its products include Fetzima and Viibryd for the treatment of major depressive disorder; Linzess to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and ...


Forest Laboratories, LLC. Forest Laboratories, LLC is now part of Allergan plc ( March 2015). See: Allergan plc. Drugs.com Mobile Apps. The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices. Explore Apps ...


Read about the history of Forest Laboratories, Inc. Explore the company's history, profile, and timeline. Find the key facts you're looking for!


Forest Laboratories, Inc. is engaged in the development, manufacture, and sale of branded forms of drug products. Its products include Bystolic, which is used to decrease heart rate and myocardial contractility; Daliresp, which is used to reduce the risk of chronic obstructive pulmonary disease exacerbation; Linzess, which ...


... online data solutions and conferences — to provide its audience with authoritative and up-to-date intelligence about corporate strategy, partnering, emerging technology, clinical data, public policy and the finance markets. Sign In Free Trial · © 2018 BioCentury Inc. All Rights Reserved. Terms & Conditions | Privacy Policy.